Santen Pharmaceutical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Santen Pharmaceutical Co., Ltd.
Plus deals involving BioLineRx/GloriaBio, Healios/Athersys, Aurobindo/Hilleman, Lupin/Menarini, GC Biopharma/Immetas, CanariaBio, Specialised Therapeutics, TaiGen/Y.S.P., Nippon/Kayaku/Adlai Nortye, WuXi/PharmaEssentia, Evommune/Maruho and Ono/Adimab.
Now more than ever, surgeons have the option to pick which robot they wish to use in surgery. Picking apart the reasons why reveals much similarity between the two surgical disciplines.
Newcomers to the market have increased the number of options available to both soft tissue and orthopedic surgeons when selecting a robot. Despite the two disciplines' differences, the factors considered by surgeons when picking a system are relatively similar.
The European Medicines Agency has OKd nine new medicines for EU-wide approval, but recommended against renewing the conditional marketing authorization of two drugs.
- Generic Drugs
- OTC, Consumer
- Implantable Devices
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Eyevance Pharmaceuticals LLC.
- Novagali Pharma SA
- Santen Inc.
- Chongqing Santen Kerui Pharmaceutical Co., Ltd
- InnFocus Inc,
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.